Literature DB >> 15481226

Retinal angiomatous proliferation: clinical characteristics and treatment options.

Megan A Hunter1, Mark T Dunbar, Phillip J Rosenfeld.   

Abstract

BACKGROUND: A new form of exudative age-related macular degeneration (ARMD), retinal angiomatous proliferation (RAP), has been described in which neovascularization begins in the deep retina, extends through the subretinal space, and eventually communicates with choroidal neovascularization.
METHODS: Case series.
RESULTS: Common clinical features of RAP include small multiple intra-retinal hemorrhages, intra-retinal edema, vascularized pigment epithelial detachments (PEDs), and retinal choroidal anastomosis (RCA). Fluorescein angiography (FA) reveals ill-defined, occult choroidal neovascularization. Indocyanine green (ICG) angiography is useful in early stages because 'hot spots' can be detected before clinical or FA characteristics are present. Optical coherence tomography (OCT) is useful in illustrating some of the clinical and FA characteristics. The use of photodynamic therapy (POT), combined with intravitreal triamcinolone injection, was successful in stabilizing the RAP lesion in one case discussed in this report.
CONCLUSIONS: Retinal angiomatous proliferation is a newly recognized entity of exudative age-related macular degeneration with its own set of clinical, FA, ICG angiography, and OCT features. Experimental treatments such as the use of PDT combined with intravitreal triamcinolone injection demonstrate potential success with this entity. The biggest hope appears to be anti-angiogenic factors currently in clinical trials for the treatment of exudative ARMD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15481226     DOI: 10.1016/s1529-1839(04)70190-6

Source DB:  PubMed          Journal:  Optometry        ISSN: 1558-1527


  11 in total

1.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Javier A Montero; Jose M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

2.  Prognosis of untreated occult choroidal neovascularization.

Authors:  Ilse Krebs; Ulrike Stolba; Carl Glittenberg; Orang Seyeddain; Thomas Benesch; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-27       Impact factor: 3.117

Review 3.  Molecular pathology of age-related macular degeneration.

Authors:  Xiaoyan Ding; Mrinali Patel; Chi-Chao Chan
Journal:  Prog Retin Eye Res       Date:  2008-11-06       Impact factor: 21.198

4.  [Intravitreal ranibizumab for the treatment of retinal angiomatous proliferation].

Authors:  J Maaß; D Sandner; E Matthé
Journal:  Ophthalmologe       Date:  2017-06       Impact factor: 1.059

5.  Intravitreal triamcinolone and laser photocoagulation for retinal angiomatous proliferation.

Authors:  T R Krieglstein; A Kampik; M Ulbig
Journal:  Br J Ophthalmol       Date:  2006-08-02       Impact factor: 4.638

6.  [Anti-VEGF treatment for retinal angiomatous proliferation].

Authors:  A Wolf; D Kook; T Kreutzer; A Gandorfer; C Haritoglou; A Kampik; M Ulbig
Journal:  Ophthalmologe       Date:  2008-09       Impact factor: 1.059

7.  Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation.

Authors:  Luis Arias; Francisco Gómez-Ulla; José M Ruiz-Moreno
Journal:  Clin Ophthalmol       Date:  2016-05-17

8.  Alterations in Circulating Immune Cells in Neovascular Age-Related Macular Degeneration.

Authors:  Judith Lechner; Mei Chen; Ruth E Hogg; Levente Toth; Giuliana Silvestri; Usha Chakravarthy; Heping Xu
Journal:  Sci Rep       Date:  2015-11-17       Impact factor: 4.379

Review 9.  Today and future of age-related macular degeneration.

Authors:  Kang Liu; Bolin Xie
Journal:  ISRN Ophthalmol       Date:  2012-04-04

10.  Higher plasma levels of complement C3a, C4a and C5a increase the risk of subretinal fibrosis in neovascular age-related macular degeneration: Complement activation in AMD.

Authors:  Judith Lechner; Mei Chen; Ruth E Hogg; Levente Toth; Giuliana Silvestri; Usha Chakravarthy; Heping Xu
Journal:  Immun Ageing       Date:  2016-02-16       Impact factor: 6.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.